www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 22), pp: 36246-36265 Research Paper Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway Stefan Garczyk1, Natalie Klotz1, Sabrina Szczepanski1, Bernd Denecke2, Wiebke Antonopoulos1, Saskia von Stillfried1, Ruth Knüchel1, Michael Rose1,* and Edgar Dahl1,* 1Molecular Oncology Group, Institute of Pathology, Medical Faculty of the RWTH Aachen University, D-52074 Aachen, Germany 2IZKF Aachen, Medical Faculty of the RWTH Aachen University, D-52074 Aachen, Germany *Equal co-senior authors Correspondence to: Stefan Garczyk, email:
[email protected] Keywords: breast cancer, metastasis, neuromedin U, neuromedin U receptor 2, WNT signaling Received: December 20, 2016 Accepted: February 07, 2017 Published: March 11, 2017 Copyright: Garczyk et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Neuromedin U (NMU) has been shown driving the progression of various tumor entities, including breast cancer. However, the expression pattern of NMU and its receptors in breast cancer tissues as well as systematic insight into mechanisms and downstream targets of the NMU-driven signaling pathways are still elusive. Here, NMU expression was found up-regulated in all breast cancer subtypes when compared to healthy breast tissue. Using an in silico dataset comprising 1,195 samples, high NMU expression was identified as an indicator of poor outcome in breast tumors showing strong NMUR2 expression. Next, the biological impact of NMU on breast cancer cells in relation to NMUR2 expression was analyzed.